Posts by: Alice Melão

News

A medicine that is commonly used against parasites like tapeworms contains a substance that stops prostate and colon cancer cells from growing, a new study found. The substance, called nitazoxanide, ... Read more

November 14, 2017November 14, 2017

ProscaVax Vaccine Stopped Prostate Cancer Progression in 80% of Patients, Phase 1 Trial Shows

News

Six injections of OncBioMune Pharmaceuticals‘ prostate cancer vaccine ProscaVax stopped the progression of the disease in 80 percent of patients in a Phase 1 clinical trial, the company announced. The results applied to ... Read more

November 13, 2017

P-PSMA-101 Generates Long-Lasting Response to Prostate Cancer, Mouse Study Shows

News

Poseida Therapeutics’ P-PSMA-101 eliminated prostate cancer in all mice that were treated in a study and prevented it from returning in two-thirds, researchers reported. The long-lasting nature of the therapy ... Read more

November 9, 2017

SOTIO Completes Enrollment for Phase 3 Trial of DCVAC/PCa Immunotherapy

News

The Phase 3 trial evaluating the immunotherapy DCVAC/PCa in men with metastatic castration-resistant prostate cancer (mCRPC), has completed patient enrollment, according to trial sponsor, SOTIO. The treatment is being evaluated as ... Read more

October 19, 2017October 19, 2017

SpaceOAR Protects Surrounding Prostate Tissues from Radiation Therapy, Phase 2 Trial Shows

News

Augmenix’s SpaceOAR System can effectively protect the rectum of prostate cancer patients undergoing high dose stereotactic body radiation therapy (SBRT), a new prospective Phase 2 trial shows. The findings were recently reported ... Read more

October 4, 2017October 4, 2017

Low-dose Brachytherapy Seen as Viable Choice for Lower Risk Patients, Long-term Study Finds

News

Patients with low-to-intermediate prostate cancer who receive low-dose permanent brachytherapy, a type of radiation therapy, have excellent outcomes in the long run, according to data recently presented at the American Society ... Read more

October 4, 2017

ProscaVax Vaccine Safe for Recurrent Prostate Cancer Patients, Phase 1a/1b Trial Shows

News

ProscaVax, a cancer vaccine developed by OncBioMune Pharmaceuticals, is safe for the treatment of recurrent prostate cancer patients, data from a Phase 1a/1b trial shows. The vaccine did not cause ... Read more

September 14, 2017

Favorable Interim Data Presented for Tyme’s SM-88 Phase 2 Trial for Prostate Cancer Patients

News

Tyme Technologies‘ SM-88 reduced the levels of circulating cancer cells — an indicator of metastatic disease — in all prostate cancer patients treated in an ongoing Phase 2 trial, according ... Read more

September 11, 2017September 11, 2017

Long-Term Data Further Confirm SpaceOAR Hydrogel Quality-of-Life Benefits

News

Prostate cancer patients who received the SpaceOAR hydrogel before radiation therapy continue to report benefits five years after treatment, including better urinary and sexual function, a new study reported. The ... Read more

September 1, 2017September 1, 2017

NICE Approves SpaceOAR Hydrogel Use in UK

News

The National Institute for Health and Care Excellence (NICE) in the U.K. has issued a guidance for prostate cancer care that supports the use of SpaceOAR hydrogel as a protective barrier to reduce the ... Read more